ArticleOphthalmology science2026
Design and Baseline Characteristics of the Korean Age-Related Maculopathy Study (KARMS): A Nationwide Multicenter Prospective Observational Study.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To describe the design and baseline characteristics of the Korean Age-Related Maculopathy Study, a nationwide prospective cohort investigating age-related macular degeneration (AMD) in Koreans. Design: A 5-year prospective observational study conducted across 33 tertiary hospitals and ophthalmology clinics in Korea. Participants: A total of 1159 Korean participants diagnosed with nonexudative or exudative AMD. Methods: Participants aged 50 to 80 years were assigned to the A Study for Intermediate AMD Natural Outcome (ASIANO) arm (nonexudative) or Korean Exudative AMD Treatment Study (KEATS) arm (newly diagnosed exudative AMD). A Study for Intermediate AMD Natural Outcome arm 1 included bilateral intermediate AMD with classic drusen (soft, reticular pseudodrusen, cuticular, or calcified drusen) without advanced AMD. A Study for Intermediate AMD Natural Outcome arm 2 included pachychoroid spectrum disease with unilateral or bilateral findings such as pachydrusen with retinal pigment epithelium undulation, focal attenuation of inner choroidal vessel, and dilated outer choroidal vessels or pigmentary abnormalities corresponding retinal pigment epithelium elevation or disruption in OCT, without significant classic drusen. The KEATS arm comprised active exudative AMD, including typical exudative macular neovascularization, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation. All underwent standardized multimodal imaging at baseline and are followed annually. Main Outcome Measures: Baseline demographic, behavioral, and ocular characteristics across drusen-driven, pachychoroid-driven, and exudative AMD phenotypes. Results: Of the 1409 individuals screened, 1159 were enrolled (ASIANO 1: 551; ASIANO 2: 317; KEATS: 291). A Study for Intermediate AMD Natural Outcome arm 1 participants were older, predominantly female, and universally bilateral; arm 2 participants were younger, more often male, and frequently unilateral. Korean Exudative AMD Treatment Study showed a high proportion of patients with polypodal choroidal vasculopathy (39.5%, patient-based) and male predominance. Behavioral profiles also differed: the KEATS arm had lower eye-supplement use, higher smoking exposure, and less frequent sunglasses/sun-visor use. Exploratory follow-up analyses suggested differing rates of exudative conversion between ASIANO arm 1 and arm 2. Conclusions: Korean Age-Related Maculopathy Study is the first large-scale, nationally representative prospective cohort in Koreans, distinguishing drusen-driven and pachychoroid-driven maculopathy phenotypes and detailing exudative subtypes. These baseline data provide a foundation for future phenotype-specific progression analyses and management strategies in Asian populations. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.